Fellow's quick read · Infectious Diseases
Cryptococcosis
ECMM / ISHAM / ASM Global Guideline 2024 (Chang, Lancet Infect Dis) · reviewed 2026-07-01
Personal study digest for a new ID fellow. Recommendations are from the ECMM/ISHAM/ASM 2024 global guideline (grades A–D, evidence levels I–III shown in parentheses). The "What's changed since 2024" section is reviewer synthesis of newer evidence, each claim cited. Not a substitute for the full guideline.
In one line
Cryptococcal meningitis is the lethal syndrome (10-week mortality 24–47% in low-income settings). Survival hinges on three fellow-owned moves: an amphotericin + FLUCYTOSINE induction backbone (never fluconazole alone), aggressive intracranial-pressure control with therapeutic LPs, and delaying ART 4–6 weeks — not the antifungal choice alone.◆When to suspect / diagnose
- At-risk hosts: HIV with CD4 <100 (dominant); SOT recipients (usually late, reactivation); and a growing non-HIV/non-SOT group — cirrhosis, idiopathic CD4 lymphopenia, biologics, and apparently immunocompetent people. C. gattii hits the immunocompetent (anti–GM-CSF autoantibodies) and favors lung/large cryptococcomas.
- Syndromes: subacute meningoencephalitis (headache, days–weeks), pulmonary (often subclinical), disseminated (any organ), or direct cutaneous inoculation.
- Diagnosis rests on cryptococcal antigen (CrAg, lateral flow) in CSF and blood, plus CSF/blood culture and microscopy (India ink). CrAg is the single most useful test — but blood CrAg can be NEGATIVE in SOT (single pulmonary nodules, lung transplant).
- Any confirmed/suspected cryptococcosis — including asymptomatic antigenemia — needs an LP with opening pressure and assessment for CNS, pulmonary, and other-site involvement (AIIt). A high serum CrAg mandates an LP even without neuro symptoms.
◆Workup the fellow drives
- LP with OPENING PRESSURE (a management number, not just a diagnostic), CSF CrAg titer, glucose/protein/cell count, microscopy, and culture (the metric that defines success — CSF sterility).
- Blood CrAg + cultures; brain imaging (MRI preferred); chest imaging (CT preferred).
- Exclude an underlying immunodeficiency in EVERYONE — HIV serology and CD4 count, even if the patient "looks" immunocompetent (AIII).
- Don't over-read antigen: CrAg titers do not track treatment response and antigen persists for months.
◆Empiric & definitive therapy
| Scenario | Drug / dose / route | Duration | Strength |
|---|---|---|---|
| HIV-CM induction (high-income) | Liposomal amphotericin B 3–4 mg/kg IV daily + flucytosine 25 mg/kg PO QID | 2 weeks | AIIt |
| HIV-CM induction (low-income) | Single-dose L-AmB 10 mg/kg + flucytosine 25 mg/kg QID ×14 d + fluconazole 1200 mg daily | 2 weeks | AI · AMBITION-cm |
| Non-HIV/non-SOT & SOT induction | L-AmB 3–4 mg/kg daily + flucytosine 25 mg/kg QID (single-dose regimen NOT validated here) | ≥2 weeks | AIIt |
| Consolidation | Fluconazole 400–800 mg daily (800 preferred low-income) | 8 weeks | AI |
| Maintenance | Fluconazole 200 mg daily | ≥12 months | AIIt |
| Mild isolated pulmonary | Fluconazole 400 mg daily | 6–12 months | BIIu |
| Asymptomatic CrAg+ (HIV, CD4<200, LP neg) | Fluconazole 1200 mg ×2 wk → 800 mg ×8 wk → 200 mg ×6 mo (pre-emptive) | ~6 months | AIIu |
- The induction backbone is a polyene + flucytosine — fluconazole monotherapy is inferior (≈50% 10-week mortality) and drives resistance; reserve azole-only induction for when amphotericin is truly unavailable.
- Echinocandins do NOT work against Cryptococcus (intrinsic resistance).
◆Duration & stopping
- Induction 2 weeks — but extend to 4–6 weeks if the CSF culture is still positive at 2 weeks, or for C. gattii CNS disease / cryptococcomas / non-HIV meningitis.
- Consolidation 8 weeks; maintenance ≥12 months.
- Stop maintenance after 12 months if the patient is aviremic on ART with CD4 >100 (BIIu); restart if CD4 falls <100.
- Consider a CSF-sterility check LP at end of week 1–2 before switching to consolidation (CIIu).
◆Key decisions a fellow owns
- Raised ICP is what kills early. Therapeutic LP: drain ~20–30 mL to reduce opening pressure by 50% (or to ≤20 cm CSF); repeat a scheduled LP at 48–72 h regardless of the pressure; refractory elevation → lumbar drain/shunt.
- ART timing: DELAY 4–6 weeks after starting antifungals — do NOT start early (DI). Early ART increases IRIS and death (COAT trial). Pulmonary/asymptomatic-antigenemia patients can start earlier (~2 weeks).
- Adjunctive dexamethasone is NOT routine — it is harmful (CryptoDex). Steroids only for IRIS, mass-effect cryptococcoma, or vasculitis.
- Do NOT escalate antifungals for persistent antigenemia or a persistently CrAg-positive CSF — follow culture, not antigen.
- SOT: lower immunosuppression in steps — corticosteroids and mycophenolate first, calcineurin inhibitors LAST (they have intrinsic anticryptococcal activity) — to avoid precipitating IRIS; watch tacrolimus/sirolimus levels when azoles are added.
What's changed since 2024
Reviewer synthesis of newer evidence — not the guideline. This ECMM/ISHAM/ASM guideline is recent, so most stands; below is what's newest plus a pipeline flag.
- This IS the current reference — study it, not IDSA 2010. The ECMM/ISHAM/ASM 2024 guideline (IDSA-endorsed) is the operative document and already folds in WHO 2022 (the AMBITION single-dose regimen). No newer major society guideline has published since Feb 2024. Chang, Lancet Infect Dis 2024 · 10.1016/S1473-3099(23)00731-4
- AMBITION single-dose L-AmB holds up in the real world — but only where it was studied. A Uganda implementation cohort confirms low mortality, yet the single 10 mg/kg regimen remains unvalidated in non-HIV, transplant, and high-income patients, where daily L-AmB + flucytosine stays standard. AMBITION-cm, NEJM 2022;386:1109-1120, PMID 35320642 · implementation CID 2024, 10.1093/cid/ciae413
- All-oral induction is on the horizon — EnACT. Oral lipid-nanocrystal amphotericin B (MAT2203) + flucytosine in a phase 2 Ugandan trial was better tolerated (less anemia and hypokalemia) with encouraging survival; a phase 3 (EnACT-3, NCT05541107) is enrolling. Would remove the IV-access bottleneck. Investigational — not FDA-approved (recency-sensitive, confirm status). OFID 2024;11(7):ofae346, PMID 38989533 · nurse sub-study BMC Infect Dis 2025;25:920, PMID 40665233
- Adjunctive therapy is still a dead end. Dexamethasone is harmful (CryptoDex, NEJM 2016;374:542-554); sertraline and tamoxifen were negative; adjunctive IFN-γ remains unresolved. The guideline's "against" stance is current. Beardsley, 10.1056/NEJMoa1509024
- Pre-emptive CrAg strategy is being refined. New data support adjunctive single-dose L-AmB for asymptomatic antigenemia with LOW plasma CrAg titers, and a phase III of fluconazole ± flucytosine for screen-detected antigenemia is underway. CID 2024, 10.1093/cid/ciae266 · Trials 2026, 10.1186/s13063-026-09520-x
◆Anki cards minted this run
- Adjunctive dexamethasone in HIV-CM → recommended against (harmful). CryptoDex; steroids reserved for IRIS/mass effect.
- High-income or non-HIV/transplant induction = DAILY L-AmB 3–4 mg/kg + flucytosine ×2 wk — the single-dose AMBITION regimen was only trialed in HIV/low-income.
- Persistent CrAg antigenemia is NOT failure — don't escalate antifungals or follow titers; follow CSF culture.
- Therapeutic-LP ICP target: drain ~20–30 mL to reduce OP by 50% (or ≤20 cm); scheduled LP at 48–72 h regardless of pressure.
Deduped against the deck (58 existing crypto notes): the classics were already carded — amphotericin + flucytosine induction, AMBITION single-dose (note 1781222142753), fluconazole 8-wk/12-mo consolidation-maintenance, COAT 4–6-wk ART timing (note 1723876219404), serial-LP for ICP, C. gattii/anti–GM-CSF, CrAg/India-ink diagnostics. Held under cap: pre-emptive CrAg fluconazole ladder; C. gattii/cryptococcoma 4–6-wk induction; EnACT oral amphotericin (pipeline, not yet practice).
Sources: Chang CC, et al. Global guideline for the diagnosis and management of cryptococcosis: an ECMM/ISHAM/ASM initiative. Lancet Infect Dis 2024 (online Feb 9 2024), doi:10.1016/S1473-3099(23)00731-4. Currency layer: AMBITION-cm (Jarvis, NEJM 2022;386:1109-1120, PMID 35320642, doi:10.1056/NEJMoa2111904); CryptoDex (Beardsley, NEJM 2016;374:542-554, doi:10.1056/NEJMoa1509024); COAT (Boulware, NEJM 2014;370:2487-2498, doi:10.1056/NEJMoa1312884); EnACT / oral lipid-nanocrystal amphotericin B MAT2203 (OFID 2024;11(7):ofae346, PMID 38989533, doi:10.1093/ofid/ofae346; BMC Infect Dis 2025;25:920, PMID 40665233); AMBITION implementation (CID 2024, doi:10.1093/cid/ciae413); low-titer CrAg adjunctive L-AmB (CID 2024, doi:10.1093/cid/ciae266); screen-detected antigenemia RCT (Trials 2026, doi:10.1186/s13063-026-09520-x). Literature via PubMed; DOIs resolved from PubMed/article pages.